

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5800326

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ACLARIS THERAPEUTICS, INC.	10/10/2019
RECEIVING PARTY DATA		
Name:	EPI HEALTH, LLC	
Street Address:	134 COLUMBUS ST	
City:	CHARLESTON	
State/Country:	SOUTH CAROLINA	
Postal Code:	29403	
PROPERTY NUMBERS Total: 21		
Property Type	Number	
Application Number:	12272253	
Application Number:	60988564	
Application Number:	13345472	
Application Number:	14181706	
Application Number:	14505100	
Application Number:	61419697	
Application Number:	61419693	
Application Number:	13309403	
Application Number:	14521094	
Application Number:	61443210	
Application Number:	13396165	
Application Number:	14144106	
Application Number:	16267590	
Application Number:	61507926	
Application Number:	13548009	
Application Number:	62010838	
Application Number:	62069624	
Application Number:	14737360	
Application Number:	15429873	
Application Number:	15984918	

Property Type	Number
Application Number:	16380538

CORRESPONDENCE DATA

Fax Number: (917)332-3773

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-885-5000

Email: jyeddo@blankrome.com

Correspondent Name: BLANK ROME LLP

Address Line 1: 1271 AVENUE OF THE AMERICAS

Address Line 2: 15TH FLOOR

Address Line 4: NEW YORK, NEW YORK 10020

ATTORNEY DOCKET NUMBER: 152949.00100

NAME OF SUBMITTER: JUDY YEDDO

SIGNATURE: /Judy Yeddo/

DATE SIGNED: 11/01/2019

Total Attachments: 25

source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page1.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page2.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page3.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page4.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page5.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page6.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page7.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page8.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page9.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page10.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page11.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page12.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page13.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page14.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page15.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page16.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page17.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page18.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page19.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page20.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page21.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page22.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page23.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page24.tif
source=Project Egret - Patent Assignment Agreement (Execution Version) [FE]#page25.tif

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is dated as of October 10, 2019 (“Effective Date”), and is made by and between Aclaris Therapeutics, Inc., a Delaware corporation (“Assignor”), and EPI Health, LLC, a South Carolina limited liability company (“Assignee”). Each of Assignor and Assignee may be referenced herein as a “Party,” and collectively, the “Parties.”

WITNESSETH:

WHEREAS, pursuant to that certain Asset Purchase Agreement between Assignor and Assignee dated as of October 10, 2019 (the “Purchase Agreement”), Assignor has agreed to (and cause its applicable Affiliates to) sell, convey, assign and transfer to Assignee, at the Closing, the Transferred Assets, including the Patents listed on Schedule A hereto (the “Assigned Patents”); and

WHEREAS, as a condition to the Closing, the Parties agreed to enter into this Agreement pursuant to which Assignor shall assign to Assignee all of Assignor’s right, title and interest in, to and under the Assigned Patents, as the case may be.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

1. Defined Terms; Interpretation. Capitalized terms used but not defined herein shall have the meanings given to them in the Purchase Agreement. This Agreement shall be interpreted in accordance with the rules of construction set forth in Section 9.7 of the Purchase Agreement.

2. Assignment of Rights in Assigned Patents. Effective upon the Effective Date, Assignor hereby sells, conveys, assigns and transfers to Assignee, and Assignee hereby accepts, all of Assignor’s right, title and interest in, to and under (a) the Assigned Patents, (b) all applications and registrations for the Assigned Patents, together with all non-provisionals, reissues, continuations, continuations-in-part, divisionals, revisions, extensions and reexaminations with respect thereto, and any other applications and patents claiming priority thereto, both in the United States and other jurisdictions, and (c) any and all rights, benefits, privileges and proceeds under the Assigned Patents throughout the world, including (i) any claim by Assignor against Third Parties for past, present or future infringement of the Assigned Patents, and the right to sue for and collect the same for Assignee’s own use and enjoyment, all to be held and enjoyed by Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had the assignment not been made, (ii) the exclusive right to apply for, maintain and claim priority from all registrations, renewals or extensions thereof, (iii) the exclusive right to grant licenses or other interests therein, (iv) the right to claim priority in all countries in accordance with international law, (v) the right to collect royalties and proceeds in connection with any of the foregoing and (vi) to apply for, prosecute, and seek patents throughout the world in respect of any inventions to the extent fully supported by the Assigned Patents.

3. Recording. Assignor hereby requests the Commissioner of Patents and Trademarks and the corresponding entities or agencies in any other applicable countries to record Assignee as the assignee and owner of the Assigned Patents, including any continuations, divisionals,

continuations-in-part, registrations, reissues, reexaminations or extensions thereof, and to issue any and all letters patent thereon to Assignee, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.

4. Assistance. Assignor shall not execute any writing or do any act whatsoever conflicting with the terms and conditions of this Agreement. Furthermore, Assignor will, upon reasonable request, without further or additional consideration, but at the expense of Assignee, execute, acknowledge and deliver, or cause to be executed, acknowledged and delivered, such additional instruments, notices, releases, certificates, powers of attorney, assurances, bills of sale and other documents and do such further acts, assignments, transfers and other things, in each case, as reasonably necessary to transfer to Assignee the Assigned Patents, to vest and confirm in Assignee the legal title to the Assigned Patents, and to perfect Assignee's enjoyment of this grant.


5. Miscellaneous. This Agreement is executed and delivered pursuant to, is in accordance with, and is subject to, all of the representations, warranties, covenants and indemnities set forth in the Purchase Agreement, all of which shall survive the consummation of the transactions contemplated hereby on the basis and to the extent set forth in the Purchase Agreement. Nothing contained in this Agreement shall in any way supersede, modify, replace, amend, change, rescind, waive, exceed, expand, enlarge or in any way affect the provisions set forth in the Purchase Agreement nor shall this Agreement reduce, expand or enlarge any remedies under the Purchase Agreement. In the event that any provision of this Agreement shall be construed to conflict with a provision in the Purchase Agreement, the terms of the Purchase Agreement shall control. This Agreement may be executed in any number of counterparts (including by facsimile or electronic transmission in .pdf, .tiff or any similar format), each of which shall be an original, but all of such counterparts together constitute one and the same instrument, and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and assigns. This Agreement shall be governed in all respects, including validity, interpretation, construction, performance and effect, by the internal laws of the State of Delaware, without regard to its conflict of laws principles that would result in the application of the law of any other state or jurisdiction. This Agreement may not be waived or amended except by an instrument in writing signed on behalf of each of the Parties hereto.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the undersigned has executed this Patent Assignment Agreement as of the date first set forth above.

ASSIGNOR:

ACLARIS THERAPEUTICS, INC.



By: _____

Name: Neal Walker

Title: President & CEO


[Signature Page to Patent Assignment Agreement]

PATENT
REEL: 050905 FRAME: 0294

IN WITNESS WHEREOF, the Assignee has executed this Patent Assignment Agreement as of the date first set forth above.

ASSIGNEE:

EPI HEALTH, LLC

By: 

Name: John Donofrio

Title: President

[Signature Page to Patent Assignment Agreement]

PATENT
REEL: 050905 FRAME: 0295

Schedule A

Assigned Patents

For the avoidance of doubt, the Assigned Patents includes (i) any substitutions, extensions, additions, reissues, reexaminations, renewals, divisions, continuations, continuations-in-part, or supplementary protection certificates, or patents or pending patent applications claiming priority, to the following Patents, and (ii) all foreign counterparts of any of the following Patents or those listed in clause (i).

*Recordation of assignment to Aclaris Therapeutics, Inc. still in process

**Assignment to Aclaris Therapeutics, Inc. not recorded

2400 Family (Purpura) (Non-Rhofade Assigned Patents)

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
AU	PCT National Phase	Granted	2008322411	11/17/2008	2008322411	7/17/2014	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
BR	PCT National Phase	Abandoned	PI0819075-5	11/17/2008			COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.**
CA	PCT National Phase	Granted	2,703,109	11/17/2008	2,703,109	7/18/2017	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
CN	PCT National Phase	Granted	200880116406.9	11/17/2008	200880116406.9	5/20/2015	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
EP	PCT National Phase	Granted	8850846	11/17/2008	2207424	6/4/2014	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
DE	EPO Validated State	Granted	8850846	11/17/2008	2207424	6/14/2014	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
FR	EPO Validated State	Granted	8850846	11/17/2008	2207424	6/4/2014	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.*
GB	EPO Validated State	Granted	8850846	11/17/2008	2207424	6/4/2014	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
EP	Divisional	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
AT	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.*
BE	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.*
CH	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
CZ	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
DE	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
DK	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
ES	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
FI	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
FR	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
GB	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
GR	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
HR	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
HU	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
IE	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
IS	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
IT	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
LU	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.*
MC	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
NL	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
NO	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
PL	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
PT	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
RO	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
SE	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
SI	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
SK	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
TR	EPO Validated State	Granted	14170999.8	11/17/2008	2818184	10/31/2018	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
EP	Divisional	Pending	18202816.7	11/17/2008			COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
HK	REP	Abandoned	11100638.5	11/17/2008			COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.**
IL	PCT National Phase	Granted	205704	11/17/2008	205704	10/1/2015	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
IN	PCT National Phase	Abandoned	1098/MUMNP/2010	11/17/2008			COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.**
JP	PCT National Phase	Granted	2010-534258	11/17/2008	5670196	12/26/2014	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.*

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
JP	Divisional	Granted	2014-214612	11/17/2008	5938082	5/20/2016	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.*
KR	PCT National Phase	Granted	10-2010-7013170	11/17/2008	10-1577471	12/14/2015	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
MX	PCT National Phase	Granted	MX/a/2010/005331	11/17/2008	334896	11/8/2015	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.*
US	Ordinary/Utility	Granted	12/272,253	11/17/2008	8,114,898	2/14/2012	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
US	Provisional	Expired	60/988,564	11/16/2007			COMPOSITIONS AND METHODS OF TREATING PURPURA	Aclaris Therapeutics, Inc.
US	Continuation	Granted	13/345,472	01/06/2012	8,673,953	3/18/2014	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
US	Continuation	Granted	14/181,706	02/16/2014	9,265,761	2/23/2016	COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
US	Continuation	Abandoned	14/505,100	10/02/2014			COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.
WO	PCT Application	Expired	PCT/US08/083774	11/17/2008			COMPOSITIONS AND METHODS FOR TREATING PURPURA	Aclaris Therapeutics, Inc.**

2500 Family (Cream Formulation)

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
AU	PCT National Phase	Granted	2011336449	12/01/2011	2011336449	10/20/2016	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.
AU	Divisional	Abandoned	2016238909	12/01/2011			PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.**
AU	Divisional	Pending	2018229508	12/01/2011			PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.
CA	PCT National Phase	Granted	2,819,633	12/01/2011	2819633	4/23/2019	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.
EP	PCT National Phase	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.
AT	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
BE	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
CH	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
CZ	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
DE	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
DK	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
ES	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
FR	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
GB	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
GR	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
IE	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
IT	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
NL	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
NO	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
PL	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
PT	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
RO	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
SE	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
TR	EPO Validated State	Granted	11794911.5	12/01/2011	2645993	11/2/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
EP	Divisional	Published	16196317.8	12/01/2011			PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.
HK	Rep	Granted	14103376.2	12/01/2011	HK1190307	1/5/2018	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.*
JP	PCT National Phase	Granted	2013-542183	12/01/2011	6030067	10/28/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.
TW	Ordinary/Utility	Granted	100144568	12/01/2011	1533893	5/21/2016	PHARMACEUTICAL CREAM COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
US	Provisional	Expired	61/419,697	12/03/2010			CREAM COMPOSITIONS AND METHODS OF USE	Aclaris Therapeutics, Inc.
US	Provisional	Expired	61/419,693	12/03/2010			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.
US	Ordinary/Utility	Granted	13/309,403	12/01/2011	8,883,838	11/11/2014	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.
US	Continuation	Published	14/521,094	10/22/2014			PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE	Aclaris Therapeutics, Inc.
WO	PCT Application	Expired	PCT/US11/62936	12/01/2011			PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE	Aclaris Therapeutics, Inc.***

2600 Family (Phase 2 Trial) (Non-Rhofade Assigned Patents)

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
AU	PCT National Phase	Abandoned	2012217858	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.**
AU	Divisional	Granted	2017202726	02/14/2012	06/20/2019		PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
AU	Divisional	Pending	2019203993	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
BR	PCT National Phase	Pending	BR112013020770-1	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
CA	PCT National Phase	Granted	2,827,373	02/14/2012	2,827,373	05/14/2019	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
CN	PCT National Phase	Abandoned	2012800179627	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc**
CN	Divisional	Published	201710280045.2	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
EP	PCT National Phase	Granted	12705755.2	02/14/2012	2675449	4/24/2019	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
CH	EPO Validated State	Granted	12705755.2	02/14/2012	2675449	4/24/2019	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
DE	EPO Validated State	Granted	12705755.2	02/14/2012	2675449	4/24/2019	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
ES	EPO Validated State	Granted	12705755.2	02/14/2012	2675449	4/24/2019	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
FR	EPO Validated State	Granted	12705755.2	02/14/2012	2675449	4/24/2019	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
GB	EPO Validated State	Granted	12705755.2	02/14/2012	2675449	4/24/2019	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
IT	EPO Validated State	Granted	12705755.2	02/14/2012	2675449	4/24/2019	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc
NL	EPO Validated State	Granted	12705755.2	02/14/2012	2675449	4/24/2019	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
EP	Divisional	Pending	19170085.5	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.
HK	Rep	Published	14105951	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.*
IN	PCT National Phase	Abandoned	7363/DELNP/2013	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.**
JP	PCT National Phase	Granted	2013-554551	02/14/2012	6225030	10/13/2017	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.
JP	Divisional	Granted	2017-002106	02/14/2012	6389534	8/24/2018	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
JP	Divisional	Abandoned	2018-153450	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.***
KR	PCT National Phase	Pending	10-2013-7024232	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.
KR	Divisional	Pending	10-2019-7028285	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.
RU	PCT National Phase	Granted	2013141845	02/14/2012	2648439	3/26/2018	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.
US	Provisional	Expired	61/443,210	02/15/2011			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
US	Ordinary/Utility	Abandoned	13/396,165	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.
US	Continuation	Abandoned	14/144,106	12/30/2013			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.
US	Continuation	Pending	16/267,590	02/05/2019			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.
WO	PCT Application	Expired	PCT/US12/25068	02/14/2012			PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA	Aclaris Therapeutics, Inc.**

2700 Family (Gel) (Non-Rhofade Assigned Patents)

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
AU	PCT National Phase	Abandoned	2012281059	07/12/2012			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**
BR	PCT National Phase	Abandoned	BR112014000876-0	07/12/2012			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**
CA	PCT National Phase	Abandoned	2,841,632	07/12/2012			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**
CN	PCT National Phase	Abandoned	2012800444247	07/12/2012			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**
EP	PCT National Phase	Abandoned	12762684.4	07/12/2012			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**
IN	PCT National Phase	Abandoned	406/DELNP/2014	07/12/2012			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**
JP	PCT National Phase	Abandoned	2014-520339	07/12/2012			GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**

KR	PCT National Phase	Abandoned	10-2014-7003753	07/12/2012				GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**
RU	PCT National Phase	Abandoned	2014104559	07/12/2012				GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**
US	Provisional	Expired	61/507,926	07/14/2011				GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.
US	Ordinary/Utility	Abandoned	13/548009	07/12/2012				GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.
WO	PCT Application	Expired	PCT/US2012/046547	07/12/2012				GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Aclaris Therapeutics, Inc.**

2800 Family (Phase 3 Trial)

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
AU	PCT National Phase	Pending	2015274532	06/11/2015			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.
CA	PCT National Phase	Published	2,951,725	06/11/2015			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.
EP	PCT National Phase	Published	15738161.7	06/11/2015			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.
HK	Rep	Published	17110194.4	06/11/2015			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.*
MX	PCT National Phase	Pending	MX/a/2016/016400	06/11/2015			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.
NZ	PCT National Phase	Pending	727233	06/11/2015			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.
US	Provisional	Expired	62/010,838	06/11/2014			OXYMETAZOLINE CREAM FOR THE TREATMENT OF ERYTHEMA ASSOCIATED WITH ROSACEA	Aclaris Therapeutics, Inc.
US	Provisional	Expired	62/069,624	10/28/2014			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.

Country	Application Type	Status	App. No.	Filing Date	Patent No.	Issue Date	Title	Owner
US	Ordinary/Utility	Granted	14/737,360	06/11/2015	9,801,857	10/31/2017	STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.
US	Divisional	Granted	15/429,873	02/10/2017	9,974,773	5/22/2018	STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.
US	Continuation	Granted	15/984,918	05/21/2018	10,335,391	07/02/2019	STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.
US	Continuation	Pending	16/380,538	04/10/2019			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.
WO	PCT Application	Expired	PCT/US2015-035420	06/11/2015			STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES	Aclaris Therapeutics, Inc.**